Switzerland's Idorsia 2025 revenue rises, loss narrows on strong QUVIVIQ sales

Idorsia

26/02/2026 06:08

Overview

Switzerland biopharmaceutical firm's 2025 net revenue rises to CHF 221 mln

Company reports narrowed net loss of CHF 112 mln, driven by revenue growth and lower expenses

Company more than doubled QUVIVIQ sales, strengthening financial position

Outlook

Idorsia expects 2026 QUVIVIQ sales to reach CHF 200 mln

Company plans 2026 non-GAAP operating expenses of approx. CHF 330 mln

TRYVIO/JERAYGO revenues not included in 2026 guidance due to partnership talks

Result Drivers

QUVIVIQ SALES GROWTH - Co more than doubled QUVIVIQ sales to CHF 134 mln, driven by expanded global reach and strategic alliances

PIPELINE DEVELOPMENT - Co focused on advancing pipeline with key readouts for daridorexant in pediatric insomnia and lucerastat in Fabry disease

COST MANAGEMENT - Co reduced operating expenses through restructuring, contributing to improved financial performance

Company press release: ID:nGNE2PSQ92

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
CHF 221 mln
FY EPS
-CHF 0.52
FY Net Income
-CHF 112 mln
FY EBIT
-CHF 33 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Idorsia Ltd is CHF4.50, about 20% above its February 25 closing price of CHF3.75

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)